News & Updates

Explore how AI, advanced analytics and real-world data can help identify rare disease patients earlier, reduce diagnostic delays and activate HCPs with more targeted, actionable insights.

It’s time to meet the AI-powered patient you didn’t plan for. Download the Future of Health Report to explore how today’s AI-enabled patients are navigating a fractured care journey­—and how our zero distance to the patient operating model can help you reshape healthcare.  

Patient access programs are under pressure to do more with increasingly complex workflows. This whitepaper explores how life sciences leaders are using automation and data to improve benefits verification, prior authorization, and the overall patient access experience. Download this free whitepaper to learn more.

Approval is too late to start building the commercial engine. Learn six principles that help first-launch biotech teams use the prelaunch window to build trusted AI, connected workflows and scalable commercial infrastructure before approval.

Market research is under pressure as traditional studies struggle to keep pace with the speed of business. This article explores how AI-powered simulated panels help organizations test more ideas, generate decision-grade insights in hours and make faster, more confident decisions.

Learn how high-quality, standardized research data, full-text content, and AI-powered technologies can help life sciences teams uncover deeper insights, improve decision-making, and accelerate discovery.

As regulators place increasing weight on real-world evidence, non-interventional study designs are taking on a larger role across the pharma life cycle. The problem: too many are designed backwards, built from the data that happens to be available rather than from the regulatory question they need to answer. 

Join OM1 Founder Dr. Rich Gliklich and Senior Director of Registries Michelle Leavy for a webinar that makes the case for a build-for-purpose mindset, in which every design decision flows from a clearly defined regulatory objective.

They’ll cover the evolving FDA and EMA landscape, how regulators evaluate fit-for-purpose evidence, and a single framework for designing registries, observational studies, and external control arms. They’ll discuss three real case studies spanning label expansion, long-term follow-up, and an external control arm, and the technology and AI that now make regulatory-grade RWE feasible at any scale.

A clear divide is emerging in the adoption of AI across clinical trials. Early adopters are pulling ahead and achieving measurable results while many organizations still remain stuck in isolated pilots, constrained by fragmented data, disconnected point solutions, and integration challenges.

Closing this gap requires more than deploying individual tools for specific use cases. Organizations must establish the data foundations, governance, workflows, and connected platform architecture needed to apply AI across the trial lifecycle and study portfolio.

Join industry leaders from Worldwide Clinical Trials, Everest Group and Medidata for a discussion informed by Medidata’s latest research into the state of AI in clinical trials. Explore where AI is delivering value today, how adoption is evolving, and what organizations can do to move from experimentation to sustainable, enterprise-wide implementation.

Topics will include:

• The growing performance gap between early adopters and organizations that remain in the pilot stage
• Data, integration, governance, and operational barriers that can prevent broader adoption
• How isolated AI applications limit value across the clinical trial lifecycle
• Why leaders like Worldwide Clinical Trials are shifting to a platform-wide architecture like Medidata Plus to support AI across studies and portfolios
• Where the industry is headed, from protocol simulation and virtual twins to agentic AI